Osteosarcoma: Basic science and clinical implications

被引：88

作者：

Hayden, JB

Hoang, BH

机构：

[1] Univ Calif Irvine, Med Ctr, Dept Orthopaed Surg, Orange, CA 92868 USA

[2] Oregon Hlth Sci Univ, Dept Orthopaed & Rehabil, Portland, OR 97239 USA

来源：

ORTHOPEDIC CLINICS OF NORTH AMERICA | 2006年 / 37卷 / 01期

关键词：

D O I：

10.1016/j.ocl.2005.06.004

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

Current therapy for osteosarcoma successfully treats 60% to 70%, of patients. Attempts to identify patients who will respond poorly to therapy has focused on the use of new biologic markers or microarray cluster analysis. New potential therapeutic targets, including growth factors, chemokines, transcription factors, and angiogenic factors, are being evaluated for their roles in osteosarcoma. These new targets may provide mechanisms to treat the patients who would respond poorly to standard therapy.

引用

收藏

页码：1 / +

页数：8

相关论文

共 36 条

[1] Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas [J].

Anninga, JK ;

van de Vijver, MJ ;

Cleton-Jansen, AM ;

Kristel, PMP ;

Taminiau, AHM ;

Nooij, M ;

Egeler, RM ;

Hogendoorn, PCW .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) :963-970

[2] Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].

Bielack, SS ;

Kempf-Bielack, B ;

Delling, G ;

Exner, GU ;

Flege, S ;

Helmke, K ;

Kotz, R ;

Salzer-Kuntschik, M ;

Werner, M ;

Winkelmann, W ;

Zoubek, A ;

Jürgens, H ;

Winkler, K .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790

[3]

Buckley JD, 1998, CANCER, V83, P1440, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1440::AID-CNCR23>3.0.CO

[4]

2-3

[5] Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma [J].

Cao, Y ;

Zhou, ZC ;

de Crombrugghe, B ;

Nakashima, K ;

Guan, H ;

Duan, XP ;

Jia, SF ;

Kleinerman, ES .

CANCER RESEARCH, 2005, 65 (04) :1124-1128

[6] Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma [J].

Dhaini, HR ;

Thomas, DG ;

Giordano, TJ ;

Johnson, TD ;

Biermann, JS ;

Leu, K ;

Hollenberg, PF ;

Baker, LH .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2481-2485

[7] Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma [J].

Ferrari, S ;

Bertoni, F ;

Zanella, L ;

Setola, E ;

Bacchini, P ;

Alberghini, M ;

Versari, M ;

Bacci, G .

CANCER, 2004, 100 (09) :1936-1942

[8]

Fuchs B, 2002, CLIN ORTHOP RELAT R, P40

[9]

Gorlick R, 2003, CLIN CANCER RES, V9, P5442

[10] Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup [J].

Hauben, EI ;

Weeden, S ;

Pringle, J ;

Van Marck, EA ;

Hogendoorn, PCW .

EUROPEAN JOURNAL OF CANCER, 2002, 38 (09) :1218-1225

← 1 2 3 4 →